Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
PTGX
#1031
Protagonist Therapeutics, Inc
92.080
0
+6.88%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+6.88%
Variazione Mensile
+11.68%
Variazione di 6 mesi
+22.56%
Variazione Annuale
+22.56%
Chiusura Precedente
86.150
0
Open
92.210
0
Bid
Ask
Low
92.080
0
High
92.220
0
Volume
152
Mercati
Mercato Azionario Statunitense
Salute
PTGX
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
59.6 M
61.38 M
61.98 M
62.21 M
62.52 M
63.81 M
—
Valuation ratios
Enterprise value
2.55 B
2.27 B
2.86 B
3.27 B
4.04 B
5.44 B
15.61 B
Price to earnings ratio
16.3
9.13
62
75.71
102.2
-42.6
197.31
Price to sales ratio
8.64
5.78
15.04
17.09
20.55
120.66
173.34
Price to cash flow ratio
14.2
13.64
10.56
86.57
62.72
96.28
256.13
Price to book ratio
1.4
3.72
1.25
1.37
1.58
9.03
13.23
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.05
0.01
0.02
0.05
0.06
0.07
0.19
Return on equity %
0.06
0.01
0.02
0.05
0.06
0.07
0.2
Return on invested capital %
152.87
-62.99
33.8
115.72
140.65
169.54
459.71
Gross margin %
100
100
100
100
100
100
400
Operating margin %
886.7
-19.76
68.18
758.04
985.17
677.09
2 488.48
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
710.37
2.36
41.15
626.96
834.87
596.8
2 099.78
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
10.7
12.48
17.26
16.97
13.05
12.71
59.98
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.01
0.25
0.04
0.01
0.01
0.01
0.06
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.45
-0.45
1.99
-0.45
-0.03
-0.58
0.93
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
7.59
6.44
9.12
8.98
9.03
8.92
36.06
Net current asset value per share
7.72
9.09
9.62
9.49
9.2
9.09
37.39
Tangible book value per share
8.61
10.38
10.94
10.52
10.12
9.67
41.25
Working capital per share
7
8.36
9.06
8.93
8.49
8.37
34.85
Book value per share
8.61
10.38
10.94
10.52
10.12
9.67
41.25
Notizie
Protagonist Therapeutics earnings missed by $0.35, revenue fell short of estimates
Citizens alza il target su Protagonist Therapeutics per approvazioni farmaci
Citizens raises Protagonist Therapeutics stock price target on drug approvals
Il direttore di Protagonist Therapeutics Williams vende azioni per 1,48 milioni di dollari
Protagonist Therapeutics director Williams sells $1.48 million in shares
Il direttore di Protagonist Therapeutics vende azioni per 1,67 milioni di dollari
Protagonist Therapeutics director sells $1.67 million in shares
I migliori titoli biotech da tenere d’occhio nel 2026, secondo Truist
Top Biotech Stocks to Watch in 2026, According to Truist
Obiettivo di prezzo per Protagonist Therapeutics alzato a $117 da $80 da H.C. Wainwright
Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright
Protagonist Stock: Assessing The 2026 Upside For Icotrokinra And Rusfertide (PTGX)